Implantable Defibrillators Global Market Report 2024

The implantable defibrillators market has grown steadily in recent years. It will grow from $5.46 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The expansion observed in the historical period can be attributed to factors such as the increased prevalence of cardiac disorders, advancements in clinical evidence and research, a rise in the aging population, heightened awareness and education, and collaborations and partnerships.

The implantable defibrillators market is expected to see steady growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to the integration of remote monitoring and telemedicine, the expansion of indications, a heightened focus on heart failure management, personalized medicine approaches, and the global expansion of healthcare infrastructure. Key trends expected in the forecast period involve miniaturization and design innovations, advancements in remote monitoring and connectivity, personalized therapy approaches, the emergence of leadless implantable defibrillators, and advancements in battery technology.

The expected rise in the prevalence of sudden cardiac arrest is poised to drive the growth of the implantable defibrillators market. Sudden cardiac arrest (SCA) is a condition where the heart unexpectedly stops beating, and implantable defibrillators play a vital role in providing lifesaving therapy by detecting and correcting abnormal heart rhythms that may lead to SCA. According to a report by the Journal of the American College of Cardiology, SCD causes 185,000 to 450,000 deaths annually in the US population, accounting for 7% to 18% of all fatalities. Therefore, the increasing prevalence of sudden cardiac arrest is a significant factor propelling the growth of the implantable defibrillators market.

The surge in the prevalence of diabetes is expected to be a driving force behind the growth of the implantable defibrillators market. Diabetes, a chronic metabolic disease associated with elevated blood glucose levels, can lead to severe damage to the heart, blood vessels, and other organs. Implantable cardioverter defibrillators (ICDs) play a crucial role in managing patients with diabetes, particularly those at risk of sudden cardiac death. ICDs have demonstrated effectiveness in reducing arrhythmic death and all-cause mortality in patients with severe myocardial dysfunction, including those with diabetes. According to the International Diabetes Federation, diabetes affected 537 million adults (20-79 years old) in 2021, with predictions indicating an increase to 643 million by 2030 and a total of 783 million by 2045. Thus, the rising prevalence of diabetes is a key driver fueling the growth of the implantable defibrillators market.

A noteworthy trend in the implantable defibrillators market is the emphasis on product innovations by major companies. These companies are focusing on developing new products to maintain their competitive edge. For example, in December 2023, Medtronic, an Ireland-based medical device company, introduced a novel type of implantable cardioverter-defibrillator called the Aurora extravascular ICD. Unsuch as traditional transvenous ICDs, this device is inserted under the skin beneath the left armpit, providing defibrillation during cardiac arrest and ongoing pacemaker therapies. It features Epsila leads that are minimally invasively connected to the heart beneath the breastbone. Additionally, the implant incorporates Medtronic's Smart Sense technology, aimed at reducing the risk of unwarranted shocks, and SureScan technology, allowing patients to undergo MRI tests with the device in place.

Major companies operating in the implantable defibrillators market are also focused on introducing advanced Cardiac Rhythm Management (CRM) devices with cutting-edge features to drive market revenues. These devices, equipped with innovative technology, monitor and manage cardiac issues effectively. For instance, in October 2023, MicroPort CRM, a France-based developer and manufacturer of cardiac pacemakers and implantable cardiac defibrillators, launched the ULYS Implantable Cardioverter Defibrillator (ICDs) and the INVICTA defibrillation lead in Japan. The ULYS ICD, with its cutting-edge technology and low current consumption, is expected to have a significantly longer lifespan than conventional ICD devices. The INVICTA defibrillation lead, designed to continuously detect electrical signals from the heart's right ventricle, provides defibrillation shocks or pacing therapy in the case of a potentially fatal ventricular tachyarrhythmia.

In December 2022, Johnson & Johnson Services Inc., a US-based healthcare product manufacturer, completed the acquisition of Abiomed for $16.6 billion. This strategic move allowed Johnson & Johnson to enhance its global market-leading Biosense Webster electrophysiology business by adding heart recovery technologies from Abiomed, expanding its portfolio in rapidly growing cardiovascular areas, including implantable defibrillators. Abiomed is a US-based provider of cardiovascular medical technology specializing in treating heart failure and coronary artery disease.

Major companies operating in the implantable defibrillators market report are Boston Scientific Corporation, LivaNova PLC, Biotronik SE & Co KG, MicroPort Scientific Corporation, Mayo Clinic, Medtronic plc, St. Jude Medical Inc., Abbott Laboratories, Sorin Group Italia S.r.l., Nihon Kohden Corporation, Koninklijke Philips N.V., Fukuda Denshi Co Ltd., Stryker Corporation, Progetti S.r.l., Imricor Medical Systems Inc., MRI Interventions Inc., ZOLL Medical Corporation, Physio-Control International Inc., Cardiac Science Corporation, Defibtech LLC, HeartSine Technologies LLC, Welch Allyn Inc., Schiller AG, CU Medical Systems Inc., Mindray Medical International Limited, Shenzhen Mindray Bio-Medical Electronics Co Ltd., Beijing M&B Electronic Instruments Co Ltd., Bexen Cardio SL, Pacemaker Technologies, Reva Medical Inc., Cardiac Insight Technologies, EBR Systems Inc., BioSensis Pty Ltd.

North America was the largest region in the implantable defibrillators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global implanted defibrillator market forecast period. The regions covered in the implantable defibrillators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable defibrillators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of implantable defibrillators include single-chambered implantable defibrillators, dual-chambered implantable defibrillators, and biventricular implantable defibrillators. Single-chamber implantable defibrillators have only one right ventricular ICD shocking coil lead placed inside the heart's right ventricle. These devices continuously monitor the patient's heart rate and rhythm and can deliver electrical shocks to the heart. The main procedures for implantation are trans-venous implantable defibrillators and subcutaneous implantable defibrillators, utilized by hospitals and clinics, ambulatory surgery centers, and other end-users.

The implantable defibrillators market research report provides implantable defibrillators market statistics, including implantable defibrillators industry global market size, regional shares, competitors with an implantable defibrillators market share, detailed implantable defibrillators market segments, market trends and opportunities, and any further data you may need to thrive in the implantable defibrillators industry. The implantable defibrillators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The implantable defibrillator market consists of sales of epicardial implantable cardioverter-defibrillator, substernal implantable cardioverter-defibrillator, and single-chamber ICD with atrial sensing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.